tradingkey.logo
tradingkey.logo
Buscar

InspireMD Inc

NSPR
Añadir a la lista de seguimiento
0.682USD
-0.018-2.51%
Cierre 07/01, 16:00ETCotizaciones retrasadas 15 min
31.97MCap. mercado
PérdidaP/E TTM

Más Datos de InspireMD Inc Compañía

InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.

Información de InspireMD Inc

Símbolo de cotizaciónNSPR
Nombre de la empresaInspireMD Inc
Fecha de salida a bolsaApr 12, 2013
Director ejecutivoSlosman (Marvin L)
Número de empleados85
Tipo de seguridadOrdinary Share
Fin del año fiscalApr 12
Dirección6303 Waterford District Drive
CiudadMIAMI
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal33126
Teléfono18887766804
Sitio Webhttps://www.inspiremd.com/en/
Símbolo de cotizaciónNSPR
Fecha de salida a bolsaApr 12, 2013
Director ejecutivoSlosman (Marvin L)

Ejecutivos de InspireMD Inc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Andrea Tommasoli
Mr. Andrea Tommasoli
Chief Operating Officer
Chief Operating Officer
954.39K
--
Dr. Gary S. Roubin, M.D., Ph.D.
Dr. Gary S. Roubin, M.D., Ph.D.
Independent Director
Independent Director
834.48K
+10.79%
Mr. Michael Berman
Mr. Michael Berman
Independent Director
Independent Director
597.58K
+10.25%
Ms. Kathryn Arnold
Ms. Kathryn Arnold
Independent Director
Independent Director
303.09K
+18.33%
Mr. Danny L. (Dan) Dearen
Mr. Danny L. (Dan) Dearen
Independent Director
Independent Director
100.05K
-2.00%
Mr. Paul S. Stuka
Mr. Paul S. Stuka
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Marvin L. Slosman
Mr. Marvin L. Slosman
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Amir Kohen
Mr. Amir Kohen
Vice President - Finance, Human Resources
Vice President - Finance, Human Resources
--
--
Mr. Shane Gleason
Mr. Shane Gleason
Vice President - Global Marketing, General Manager, North America
Vice President - Global Marketing, General Manager, North America
--
--
Mr. Scott R. Ward
Mr. Scott R. Ward
Director
Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Andrea Tommasoli
Mr. Andrea Tommasoli
Chief Operating Officer
Chief Operating Officer
954.39K
--
Dr. Gary S. Roubin, M.D., Ph.D.
Dr. Gary S. Roubin, M.D., Ph.D.
Independent Director
Independent Director
834.48K
+10.79%
Mr. Michael Berman
Mr. Michael Berman
Independent Director
Independent Director
597.58K
+10.25%
Ms. Kathryn Arnold
Ms. Kathryn Arnold
Independent Director
Independent Director
303.09K
+18.33%
Mr. Danny L. (Dan) Dearen
Mr. Danny L. (Dan) Dearen
Independent Director
Independent Director
100.05K
-2.00%
Mr. Paul S. Stuka
Mr. Paul S. Stuka
Independent Chairman of the Board
Independent Chairman of the Board
--
--

Preguntas frecuentes

¿Quiénes son los cinco principales accionistas de InspireMD Inc?

Los cinco principales accionistas de InspireMD Inc son: Mr. Andrea Tommasoli

¿Cuántas instituciones poseen acciones de InspireMD Inc (NSPR)?

A fecha de 2026Q1, 67 instituciones poseen acciones de InspireMD Inc, con un valor de mercado combinado de aproximadamente 23.13M, lo que representa el 49.38% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -455014.00.